Novartis (NVS) Earnings Date, Estimates & Call Transcripts $115.89 +2.39 (+2.10%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$115.50 -0.39 (-0.34%) As of 08/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Novartis Earnings Summary Novartis released Q2 2025 earnings on July 17, 2025, reporting an EPS of $2.42, which beat the consensus estimate of $2.38 by $0.04. Quarterly revenue rose 12.3% year-over-year to $14.05 billion, above analysts' expectations of $13.94 billion. With a trailing EPS of $6.87 and a P/E Ratio of 16.87, Novartis' earnings are expected to grow 4.26% next year, from $8.45 to $8.81 per share. Latest Q2 Earnings DateJul. 17EstimatedConsensus EPS (Jul. 17) $2.38 Actual EPS (Jul. 17) $2.42 Beat By $0.04 Actual Revenue (Jul. 17) $14.05BQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Interim Report Slide DeckSlide DeckFull Screen Slide DeckPowered by Get Novartis Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novartis and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNVS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NVS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Novartis Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251$1.96$1.96$1.96Q2 20251$2.34$2.34$2.34Q3 20251$2.25$2.25$2.25Q4 20251$2.09$2.09$2.09 FY 2025 4 $8.64 $8.64 $8.64 Q1 20261$2.26$2.26$2.26Q2 20261$2.69$2.69$2.69Q3 20261$2.21$2.21$2.21Q4 20261$2.16$2.16$2.16 FY 2026 4 $9.32 $9.32 $9.32 Q1 20271$2.26$2.26$2.26Q2 20271$3.20$3.20$3.20 Novartis Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails7/17/2025Q2 2025$2.38$2.42+$0.04$2.06$13.94B$14.05B4/29/2025Q1 2025$2.12$2.28+$0.16$1.83$12.92B$13.23B1/31/2025Q4 2024$1.80$1.98+$0.18$1.41$12.86B-10/29/2024Q3 2024$1.94$2.06+$0.12$2.55$12.62B$12.82B7/18/2024Q2 2024$1.87$1.97+$0.10$2.35$12.24B$12.87B4/23/2024Q1 2024$1.73$1.80+$0.07$2.29$11.50B$11.83B1/30/2024Q4 2023$1.64$1.53 -$0.11-$1.08$11.69B$11.42B10/23/2023Q3 2023$1.70$1.74+$0.04$2.63$12.05B$11.78B Novartis Earnings - Frequently Asked Questions When did Novartis announce their last quarterly earnings? Novartis (NYSE:NVS) last announced its quarterly earning data on Thursday, July 17, 2025. Learn more on NVS's earnings history. Did Novartis beat their earnings estimates last quarter? In the previous quarter, Novartis (NYSE:NVS) reported $2.42 earnings per share (EPS) to beat the analysts' consensus estimate of $2.38 by $0.04. Learn more on analysts' earnings estimate vs. NVS's actual earnings. How can I listen to Novartis' earnings conference call? The conference call for Novartis' latest earnings report can be listened to online. Listen to Conference Call How can I read Novartis' conference call transcript? The conference call transcript for Novartis' latest earnings report can be read online. Read Transcript How much revenue does Novartis generate each year? Novartis (NYSE:NVS) has a recorded annual revenue of $50.32 billion. How much profit does Novartis generate each year? Novartis (NYSE:NVS) has a recorded net income of $11.94 billion. NVS has generated $6.87 earnings per share over the last four quarters. What is Novartis' price-to-earnings ratio? Novartis (NYSE:NVS) has a trailing price-to-earnings ratio of 16.87 and a forward price-to-earnings ratio of 13.71. The price/earnings-to-growth ratio is 1.6. What is Novartis' EPS forecast for next year? Novartis' earnings are expected to grow from $8.45 per share to $8.81 per share in the next year, which is a 4.26% increase. More Earnings Resources from MarketBeat Related Companies AstraZeneca Earnings Date Novo Nordisk A/S Earnings Date Sanofi Earnings Date GSK Earnings Date Takeda Pharmaceutical Earnings Date argenex Earnings Date BeOne Medicines Earnings Date BioNTech Earnings Date Insmed Earnings Date Summit Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a RallyRivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk Production This page (NYSE:NVS) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novartis AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Novartis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
